News in brief: Cheap Chinese checkpoint inhibitors; Novel agent for DIPG; Value in CBT to cut fear of cancer recurrence 

Made in China ICIs to shake up oncology market Cheap immune checkpoint inhibitors  from China are set to revolutionise the immune-oncology market globally by driving down prices, according to analytics company GlobalData. A new generation of Chinese domestic checkpoint inhibitor products such as the anti–PD-1 agents tislelizumab and camrelizumab are 75% less expensive than international brands ...

Already a member?

Login to keep reading.

© 2022 the limbic